Diagnosis and Management of Status Epilepticus

Abstract

Seizures are among the most common neurological presentations to the emergency room. They present on a spectrum of severity from isolated new-onset seizures to acute repetitive seizures and, in severe cases, status epilepticus. The latter is the most serious, as it is associated with high morbidity and mortality. Prompt recognition and treatment of both seizure activity and associated acute systemic complications are essential to improve the overall outcome of these patients. The purpose of this review is to provide the current viewpoint on the diagnostic evaluation and pharmacological management of patients presenting with status epilepticus, and the common associated systemic complications.

Keywords

causes of status epilepticus - treatment of status epilepticus - complications of status epilepticus - autoimmune encephalitis

Publication History

Article published online:
07 October 2021

• References

• 1 Hauser WA. Status epilepticus: epidemiologic considerations. Neurology 1990; 40 (05, Suppl 2): 9-13
• 2 Trinka E, Cock H, Hesdorffer D. et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia 2015; 56 (10) 1515-1523
• 3 Lowenstein DH, Bleck T, Macdonald RL. It's time to revise the definition of status epilepticus. Epilepsia 1999; 40 (01) 120-122
• 4 Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol 2015; 14 (06) 615-624
• 5 Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011; 134 (Pt, 10): 2802-2818
• 6 Trinka E, Höfler J, Zerbs A. Causes of status epilepticus. Epilepsia 2012; 53 (Suppl. 04) 127-138
• 7 Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus. Epilepsia 2001; 42 (08) 1031-1035
• 8 Dham BS, Hunter K, Rincon F. The epidemiology of status epilepticus in the United States. Neurocrit Care 2014; 20 (03) 476-483
• 9 Leitinger M, Trinka E, Giovannini G. et al. Epidemiology of status epilepticus in adults: a population-based study on incidence, causes, and outcomes. Epilepsia 2019; 60 (01) 53-62
• 10 DeLorenzo RJ, Hauser WA, Towne AR. et al. A prospective, population-based epidemiologic study of status epilepticus in Richmond, Virginia. Neurology 1996; 46 (04) 1029-1035
• 11 Hesdorber DC, Annegers JF, Cascino G, Annegers JF, Hauser WA. Incidence of status epilepticus in Rochester, Minnesota, 1965-1984. Neurology 1998; 50 (03) 735-741
• 12 DeLorenzo RJ, Pellock JM, Towne AR, Boggs JG. Epidemiology of status epilepticus. J Clin Neurophysiol 1995; 12 (04) 316-325
• 13 Gaspard N, Foreman BP, Alvarez V. et al; Critical Care EEG Monitoring Research Consortium (CCEMRC). New-onset refractory status epilepticus: etiology, clinical features, and outcome. Neurology 2015; 85 (18) 1604-1613
• 14 Costello DJ, Kilbride RD, Cole AJ. Cryptogenic new onset refractory status epilepticus (NORSE) in adults—Infectious or not?. J Neurol Sci 2009; 277 (1-2): 26-31
• 15 Hirsch LJ, Gaspard N, van Baalen A. et al. Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 2018; 59 (04) 739-744
• 16 Glauser T, Shinnar S, Gloss D. et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the guideline committee of the American Epilepsy Society. Epilepsy Curr 2016; 16 (01) 48-61
• 17 Claassen J, Mayer SA, Kowalski RG, Emerson RG, Hirsch LJ. Detection of electrographic seizures with continuous EEG monitoring in critically ill patients. Neurology 2004; 62 (10) 1743-1748
• 18 DeLorenzo RJ, Waterhouse EJ, Towne AR. et al. Persistent nonconvulsive status epilepticus after the control of convulsive status epilepticus. Epilepsia 1998; 39 (08) 833-840
• 19 Hill CE, Blank LJ, Thibault D. et al. Continuous EEG is associated with favorable hospitalization outcomes for critically ill patients. Neurology 2019; 92 (01) e9-e18
• 20 Rossetti AO, Schindler K, Sutter R. et al. Continuous vs routine electroencephalogram in critically ill adults with altered consciousness and no recent seizure: a multicenter randomized clinical trial. JAMA Neurol 2020; 77 (10) 1-8
• 21 Brophy GM, Bell R, Claassen J. et al; Neurocritical Care Society Status Epilepticus Guideline Writing Committee. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care 2012; 17 (01) 3-23
• 22 Treiman DM, Meyers PD, Walton NY. et al; Veterans Affairs Status Epilepticus Cooperative Study Group. A comparison of four treatments for generalized convulsive status epilepticus. N Engl J Med 1998; 339 (12) 792-798
• 23 Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patrick B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA 1983; 249 (11) 1452-1454
• 24 Chamberlain JM, Altieri MA, Futterman C, Young GM, Ochsenschlager DW, Waisman Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care 1997; 13 (02) 92-94
• 25 Scott RC, Besag FMC, Neville BGR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet 1999; 353 (9153): 623-626
• 26 Scheepers M, Scheepers B, Clarke M, Comish S, Ibitoye M. Is intranasal midazolam an effective rescue medication in adolescents and adults with severe epilepsy?. Seizure 2000; 9 (06) 417-422
• 27 Kapur J, Elm J, Chamberlain JM. et al; NETT and PECARN Investigators. Randomized trial of three anticonvulsant medications for status epilepticus. N Engl J Med 2019; 381 (22) 2103-2113
• 28 Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia 2010; 51 (02) 251-256
• 29 Panebianco M, Marson A. Refractory status epilepticus. Essentials Neuroanesthesia 2017; 59: 309-314
• 30 Rossetti AO. Management of refractory status epilepticus in adults: still more questions than answers. Lancet Neurol 2011; 10 (10) 922-930
• 31 Reznik ME, Berger K, Claassen J. Comparison of intravenous anesthetic agents for the treatment of refractory status epilepticus. J Clin Med 2016; 5 (05) 54
• 32 Claassen J, Hirsch LJ, Emerson RG, Mayer SA. Treatment of refractory status epilepticus with pentobarbital, propofol, or midazolam: a systematic review. Epilepsia 2002; 43 (02) 146-153
• 33 Hanley DF, Kross JF. Use of midazolam in the treatment of refractory status epilepticus. Clin Ther 1998; 20 (06) 1093-1105
• 34 Naritoku DK, Sinha S. Prolongation of midazolam half-life after sustained infusion for status epilepticus. Neurology 2000; 54 (06) 1366-1368
• 35 Stecker MM, Kramer TH, Raps EC, O'Meeghan R, Dulaney E, Skaar DJ. Treatment of refractory status epilepticus with propofol: clinical and pharmacokinetic findings. Epilepsia 1998; 39 (01) 18-26
• 36 Gaspard N, Foreman B, Judd LM. et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia 2013; 54 (08) 1498-1503
• 37 Hocker SE, Shorvon S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology 2014; 83 (09) 866
• 38 Mahmoud SH, Rans C. Systematic review of clobazam use in patients with status epilepticus. Epilepsia Open 2018; 3 (03) 323-330
• 39 Fechner A, Hubert K, Jahnke K. et al. Treatment of refractory and superrefractory status epilepticus with topiramate: a cohort study of 106 patients and a review of the literature. Epilepsia 2019; 60 (12) 2448-2458
• 40 Rohracher A, Kalss G, Neuray C. et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit: a single-center audit of 30 patients. Epilepsia 2018; 59 (May, Suppl 2): 234-242
• 41 Strzelczyk A, Steinig I, Willems LM. et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 2017; 70 (Pt A): 177-181
• 42 Trinka E, Brigo F. Neurostimulation in the treatment of refractory and super-refractory status epilepticus. Epilepsy Behav 2019; 101 (Pt B) 106551
• 43 Muhlhofer WG, Layfield S, Lowenstein D. et al. Duration of therapeutic coma and outcome of refractory status epilepticus. Epilepsia 2019; 60 (05) 921-934
• 44 Schubert J, Brämer D, Huttner HB. et al; GENERATE and IGNITE Network. Management and prognostic markers in patients with autoimmune encephalitis requiring ICU treatment. Neurol Neuroimmunol Neuroinflamm 2018; 6 (01) e514
• 45 Dubey D, Alqallaf A, Hays R. et al. Neurological autoantibody prevalence in epilepsy of unknown etiology. JAMA Neurol 2017; 74 (04) 397-402
• 46 Steriade C, Britton J, Dale RC. et al. Acute symptomatic seizures secondary to autoimmune encephalitis and autoimmune-associated epilepsy: conceptual definitions. Epilepsia 2020; 61 (07) 1341-1351
• 47 Davis R, Dalmau J. Autoimmunity, seizures, and status epilepticus. Epilepsia 2013; 54 (Suppl. 06) 46-49
• 48 Probasco JC, Solnes L, Nalluri A. et al. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 2017; 4 (04) e352
• 49 Cabezudo-García P, Mena-Vázquez N, Villagrán-García M, Serrano-Castro PJ. Efficacy of antiepileptic drugs in autoimmune epilepsy: a systematic review. Seizure 2018; 59: 72-76
• 50 Shin YW, Lee ST, Park KI. et al. Treatment strategies for autoimmune encephalitis. Ther Adv Neurol Disord 2017; 11: 1756285617722347
• 51 Hantus S. Epilepsy emergencies. Continuum (Minneap Minn) 2016; 22 (1 Epilepsy): 173-190
• 52 Linnoila J, Pittock SJ. Autoantibody-associated central nervous system neurologic disorders. Semin Neurol 2016; 36 (04) 382-396
• 53 Kanter IC, Huttner HB, Staykov D. et al. Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus. Epilepsia 2008; 49 (05) 914-920
• 54 Triplett J, Vijayan S, MacDonald A. et al. Fulminant anti-GAD antibody encephalitis presenting with status epilepticus requiring aggressive immunosuppression. J Neuroimmunol 2018; 323: 119-124
• 55 Hawkes MA, Hocker SE. Systemic complications following status epilepticus. Curr Neurol Neurosci Rep 2018; 18 (02) 7
• 56 Sutter R, Dittrich T, Semmlack S, Rüegg S, Marsch S, Kaplan PW. Acute systemic complications of convulsive status epilepticus—a systematic review. Crit Care Med 2018; 46 (01) 138-145
• 57 Vohra TT, Miller JB, Nicholas KS. et al; Neurological Emergencies Treatment Trials (NETT) Investigators. Endotracheal intubation in patients treated for prehospital status epilepticus. Neurocrit Care 2015; 23 (01) 33-43
• 58 Kennedy JD, Hardin KA, Parikh P, Li CS, Seyal M. Pulmonary edema following generalized tonic clonic seizures is directly associated with seizure duration. Seizure 2015; 27: 19-24
• 59 Baumann A, Audibert G, McDonnell J, Mertes PM. Neurogenic pulmonary edema. Acta Anaesthesiol Scand 2007; 51 (04) 447-455
• 60 Boggs JG, Painter JA, DeLorenzo RJ. Analysis of electrocardiographic changes in status epilepticus. Epilepsy Res 1993; 14 (01) 87-94
• 61 Eue S, Grumbt M, Müller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav 2009; 15 (04) 467-469
• 62 Stöllberger C, Wegner C, Finsterer J. Seizure-associated takotsubo cardiomyopathy. Epilepsia 2011; 52 (11) e160-e167
• 63 Lemke DM, Hussain SI, Wolfe TJ. et al. Takotsubo cardiomyopathy associated with seizures. Neurocrit Care 2008; 9 (01) 112-117
• 64 Degiorgio CM. Atrial flutter/atrial fibrillation associated with lacosamide for partial seizures. Epilepsy Behav 2010; 18 (03) 322-324
• 65 Corbellini AB, Hristova V, Garcia A. et al. Cardioembolic ischemic stroke in the context of atrial fibrillation after low-dose intravenous infusion of lacosamide: case report and literature review. Eur J Neurol 2019; 26 (s1): 406-407
• 66 Miller MA, Forni A, Yogaratnam D. Propylene glycol-induced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother 2008; 42 (10) 1502-1506
• 67 Semmlack S, Tschudin-Sutter S, Widmer AF. et al. Independent impact of infections on the course and outcome of status epilepticus: a 10-year cohort study. J Neurol 2016; 263 (07) 1303-1313
• 68 Belluzzo M, Furlanis G, Stragapede L, Monti F. Role of comorbidities and in-hospital complications in short-term status epilepticus outcome. Clin Neurol Neurosurg 2017; 154: 13-18
• 69 Scholtes FB, Renier WO, Meinardi H. Generalized convulsive status epilepticus: causes, therapy, and outcome in 346 patients. Epilepsia 1994; 35 (05) 1104-1112
• 70 Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia 1994; 35 (01) 27-34
• 71 Claassen J, Lokin JK, Fitzsimmons B-FM, Mendelsohn FA, Mayer SA. Predictors of functional disability and mortality after status epilepticus. Neurology 2002; 58 (01) 139-142